Nisa Investment Advisors, LLC Mirati Therapeutics, Inc. Transaction History

Nisa Investment Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$59.5 - $86.7 $458,685 - $668,370	7,709 Added 67.09%	19,200 $1.34 Million
Q2 2022 Aug 03, 2022	BUY	$39.16 - $88.71 $348,523 - $789,519	8,900 Added 343.5%	11,491 $771,000
Q1 2022 Apr 29, 2022	BUY	$75.82 - $150.97 $59,442 - $118,360	784 Added 43.39%	2,591 $213,000
Q4 2021 Feb 03, 2022	SELL	$132.01 - $190.29 $27,722 - $39,960	-210 Reduced 10.41%	1,807 $216,000
Q3 2021 Oct 18, 2021	BUY	$132.13 - $177.45 $5,945 - $7,985	45 Added 2.28%	2,017 $357,000

Q2 2021 Aug 06, 2021	SELL	$144.0 - $179.73 $194,400 - $242,635	-1,350 Reduced 40.64%	1,972 $319,000
Q4 2020 Jan 25, 2021	BUY	$162.05 - $240.27 $343,870 - $509,852	2,122 Added 176.83%	3,322 $730,000
Q3 2020 Oct 20, 2020	BUY	$113.26 - $167.27 $101,934 - $150,543	900 Added 300.0%	1,200 $199,000
Q2 2020 Jul 27, 2020	BUY	$72.01 - $120.39 $5,760 - $9,631	80 Added 36.36%	300 $34,000
Q1 2020 Apr 17, 2020	SELL	$69.78 - $116.21 $3,489 - $5,810	-50 Reduced 18.52%	220 $17,000
Q4 2019 Jan 17, 2020	BUY	$70.76 - $128.86 $8,491 - $15,463	120 Added 80.0%	270 $35,000
Q1 2019 Apr 17, 2019	BUY	$43.65 - $78.95 $6,547 - $11,842	150 New	150 $11,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nisa Investment Advisors, LLC with notifications on news.